Back to Search
Start Over
Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
- Source :
-
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2011 Sep; Vol. 17 (3), pp. 147-54. Date of Electronic Publication: 2010 Mar 23. - Publication Year :
- 2011
-
Abstract
- Purpose: Rasburicase is a recombinant urate oxidase enzyme generally reserved for the treatment or prevention of hyperuricemia in patients that are at high risk of developing tumor lysis syndrome (TLS). The primary objective of this study is to evaluate and characterize the outcomes of patients receiving low dose rasburicase for treatment or prophylaxis of hyperuricemia secondary to TLS.<br />Patients/methods: A retrospective chart review between April 1, 2007 and September 31, 2008 was completed. All adult patients who received a dose of 0.05mg/kg with either a leukemia or lymphoma diagnosis in addition to at least two TLS risk factors: WBC ≥ 50 × 109/L, LDH 2 × ULN, uric acid ≥ 8 mg/dl, SCr ≥ 1.5 mg/dl were included. Forty-eight patients received rasburicase for prophylaxis (n = 18) or treatment (n = 30) of TLS.<br />Results: Forty patients achieved and maintained a uric acid less than 8 mg/dL, 24 h after receipt of a single dose of rasburicase without the requirement for renal replacement therapy. A statistically significant decrease in UA was achieved in all patients when compared to baseline (p < 0.001). Cost analysis revealed a $ 1.96 million (96%) direct cost savings for the 48 patients in this study when compared to the cost of manufacturer's dosing recommendation.<br />Conclusions: Low dose rasburicase was efficacious and cost effective for both prophylaxis and treatment of TLS. Administration of a single dose of 0.05mg/kg of rasburicase was sufficient in correcting uric acid levels for most patients.
- Subjects :
- Adult
Aged
Aged, 80 and over
Biomarkers blood
Chicago
Cost Savings
Cost-Benefit Analysis
Drug Costs
Female
Gout Suppressants economics
Humans
Hyperuricemia blood
Hyperuricemia economics
Hyperuricemia etiology
Male
Middle Aged
Retrospective Studies
Risk Factors
Treatment Outcome
Tumor Lysis Syndrome blood
Tumor Lysis Syndrome economics
Tumor Lysis Syndrome etiology
Urate Oxidase economics
Uric Acid blood
Young Adult
Body Weight
Drug Dosage Calculations
Gout Suppressants administration & dosage
Hyperuricemia drug therapy
Hyperuricemia prevention & control
Tumor Lysis Syndrome drug therapy
Tumor Lysis Syndrome prevention & control
Urate Oxidase administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1477-092X
- Volume :
- 17
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- Publication Type :
- Academic Journal
- Accession number :
- 20332174
- Full Text :
- https://doi.org/10.1177/1078155210364180